Can-Fite BioPharma to participate in BioFIT 2025

Can-Fite BioPharma (CANF) will participate in BioFIT 2025, which will be held on December 2-3, 2025, in Strasbourg, France. BioFIT 2025 is a major European conference focused on life sciences, bringing together academia, industry, and investors to facilitate technology transfer, early-stage collaborations, and investment in biotech and medtech. “Our previous participation at BioFIT led directly to our successful partnership with Vetbiolix for Piclidenoson for the treatment of osteoarthritis in dogs and cats, an agreement potentially worth an estimated $325 million in royalty revenues for Can-Fite,” stated Dr. Sari Fishman, Can-Fite’s VP of Business Development. “As we return this year, we look forward to advancing new collaborations around Namodenoson and expanding our veterinary pipeline.” At BioFIT 2025, Can-Fite aims to advance a second veterinary partnership focused on Namodenoson, its Phase III anti-cancer drug candidate. Namodenoson has demonstrated strong anti-tumor activity, complete response in human liver cancer patient and an excellent safety profile, making it a compelling candidate for veterinary oncology. In human clinical trials, Namodenoson is currently being evaluated in a Phase III liver cancer trial and Phase II pancreatic cancer study.